Fig 1: (A) Fluorescence micrographs show circumferential distribution of LepR+ cells (red) around HEVs and lymphatics in Leprcre;tdTomato mice LNs. LepR (red) colocalized with PDPN and ER-TR7. Scale bar, 50μm. (B) Fluorescence micrographs of LNs from Leprcre;tdTomato mice showed no colocalization of LepR (red) with NG2 and PDGFRβ. Scale bar, 100μm. (C) Fluorescence micrographs of Leprcre;tdTomato mice LNs showed no colocalization of LepR (red) with RANKL, CD35 and MAdCAM. Scale bar, 50μm. (D) LepR expression in CD45-PDPN+CD31-(FRCs) and CD45-PDPN-CD31-(DN) populations of LNs were evaluated by flow cytometry. Data are representative of three independent experiments (n=3). (E) Gating strategy to exclude hematopoietic and endothelial cells for LepR+ cells in LepRcre;tdTomato LNs. (F) The percentages of LepR+ cells of LNs in stromal marker panel Sca-1, CD29, CD90, CD44, CD73, CD105 and CD106 were evaluated based on the gating strategy in (E). Data are representative of three independent experiments (n=3). (G) Fluorescence micrographs of PND1 and PND14 LNs showed location of LepR+ cells (red) in relation to HEVs, lymphatics, PDPN and ER-TR7. Scale bar, 100μm.